Retatrutide Storage and Handling: Temperature, Shelf Life, and Travel (2026 Guide)
There is no official storage label for retatrutide, because the drug is still in phase 3 trials.
Retatrutide is an investigational medication in clinical trials. It is not FDA-approved, is not legally compoundable, and is not available through Trimi. Trimi does not offer it and has no plans to. This article is editorial safety coverage for people researching the drug-development pipeline.
No retatrutide-specific stability data has been published.
How Should Retatrutide Be Stored?
Eli Lilly has not published any stability or handling data for retatrutide, because the drug is still moving through the phase 3 TRIUMPH program.
Room Temperature: How Long Is Too Long?
No one knows the true room-temperature window for retatrutide, because no stability studies have been published.
Available by prescription
Looking for a medication you can actually get now?
Retatrutide is still in clinical trials and is not available anywhere outside of them. Licensed clinicians can prescribe compounded semaglutide or compounded tirzepatide when appropriate.
Start your online visitFrequently Asked Questions
What temperature should retatrutide be stored at?
There is no official storage label for retatrutide because it is still in clinical trials.
How long can retatrutide stay at room temperature?
No room-temperature stability data has been published for retatrutide.
This article is general information, not medical advice. It does not cover every situation, and it cannot account for your health history. Consult a licensed clinician or pharmacist about medication storage and any medication decision.
Related Reading
Sources & References
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM 2023. pubmed.ncbi.nlm.nih.gov/37366315
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. pubmed.ncbi.nlm.nih.gov/33567185
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. pubmed.ncbi.nlm.nih.gov/35658024
- U.S. Food and Drug Administration. Human Drug Compounding. fda.gov/drugs/human-drug-compounding
- ClinicalTrials.gov, U.S. National Library of Medicine. clinicaltrials.gov